Metastatic osteosarcoma at diagnosis

Abstract

Blends of polypropylene (PP) and thermoplastic elastomers (TPE), namely SBS (styrene‐butadiene‐styrene) and SEBS (styrene‐ethylene/1‐butene‐styrene) block copolymers, were prepared to evaluate the effectiveness of the TPE type as an impact modifier for PP and influence of the concentration of elastomer on the polymer properties. Polypropylene homopolymer (PP‐H) and ethylene–propylene random copolymer (PP‐R) were evaluated as the PP matrix. Results showed that TPEs had a nucleating effect that caused the PP crystallization temperature to increase, with SBS being more effective than SEBS. Microstructure characterization tests showed that in most cases PP/SEBS blends showed the smallest rubber droplets regardless of the matrix used. It was seen that SEBS is a more effective toughening agent for PP than SBS. At 0°C the Izod impact strength of the PP‐H/SEBS 30% b/w blend was twofold higher than the SBS strength, with the PP‐R/SEBS 30% b/w blend showing no break. A similar behavior on tensile properties and flexural modulus were observed in both PP/TPE blends. Yield stress and tensile strength decreased and elongation at break increased by expanding the dispersed elastomeric phase in the PP matrix. © 2004 Wiley Periodicals, Inc. J Appl Polym Sci 95: 254–263, 2005

A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model

“…Between 25 and 40% of patients with localized disease will suffer a metastatic recurrence, and up to 75% of these patients will die of their disease [22-25]. These numbers have not significantly changed since the 1980s, despite numerous clinical trials aimed at improving the efficacy of chemotherapy.…”

Manipulation Therapy Prior to Diagnosis Induced Primary Osteosarcoma Metastasis—From Clinical to Basic Research

“…OS has high local aggressiveness and occasionally metastasis to lung and other bone sites, with few occasions to lymphoid metastasis[4]. Recently, the combination of practicable surgery and chemotherapy improve the long-term survival of approximately 60–70% that prolong the survival rate of OS[5]. Nonetheless, issue such as complementary treatments before OS diagnosis affecting the clinical outcome remains important but less discussed.…”

Prognostic value of abnormally expressed long non-coding RNAs in patients with osteosarcoma: a meta-analysis

“…Although advances in tumor treatment strategy have significantly raised the survival rate of osteosarcoma patients, the survival of osteosarcoma patients with metastatic disease or recurrences and those in advanced stage is still quite poor [3,[6][7][8]. Thus, novel promising biomarkers of osteosarcoma that can help in diagnosis and prognosis evaluation are still urgently needed.…”

“…With the application of chemotherapy, a combination of neoadjuvant chemotherapy, surgery resection and postoperative chemotherapy has clinically become the standard treatment strategy for osteosarcoma and has significantly improved patients' outcome, the 5-year overall survival of patients with nonmetastatic osteosarcoma of the extremity has approached to 70%~80% over past decades [5,6]. However, the 5-year overall survival rate of osteosarcoma patients with detectable metastases at diagnosis is as low as 19% [7]. Those patients with recurrent disease also have unsatisfactory 5-year post-relapse-overall-survival (PROS) rate, which is about 30% [8].…”